Another study demonstrated that this inhibitor exerts a synergistic effect by inhibiting mitogen-activated protein kinase (MEK) and PI3K in ovarian mucinous carcinoma cell lines with KRAS mutations [86]. This evidence concerns the gene MAP2K7 and ovarian mucinous adenocarcinoma.